Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value

Abstract Background hepatocellular carcinoma (HCC) shows an increasing incidence and represents the third most common cause of cancer-related death. Aim of the Work is to evaluate the diagnostic value of serum level of Macrophage activation marker soluble CD163 as a tumor marker for HCC and its prognostic value after transarterial chemo-embolization (TACE) or radiofrequency ablation (RFA), in comparison to alpha-feto protein (AFP). Patients and Methods this study was performed on 60 subjects from the outpatient Hepatology clinic and inpatient Gastroenterology and Hepatology Department at Ain Shams University Hospital. Group I includes 40 randomly selected cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma (excluding BCLC class D) who underwent either RFA or TACE. Group II includes 20 patients with liver cirrhosis without hepatocellular carcinoma considered as control. Results soluble CD163 expression did not differ significantly between HCC group and liver cirrhosis group. This proves that soluble CD163 is not suitable for diagnostic use. On the other hand, soluble CD163 was associated with the severity of liver disease. Baseline soluble CD163 was significantly associated with disease progression independent of other risk factors known to be associated with an unfavorable course in HCC. Also the marked significant reduction of serum soluble CD163 levels in HCC patients subjected to either RF ablation or TACE proved that soluble CD163 may play a prognostic marker in HCC monitoring. Conclusion soluble CD163 is not suitable as a diagnostic marker for HCC but can be used as a prognostic marker for HCC.

Download Full-text

The prognostic value of peritoneoscopic findings in patients with liver cirrhosis

Gastroenterologia Japonica ◽

10.1007/bf02774311 ◽

1980 ◽

Vol 15 (4) ◽

pp. 379-384 ◽

Cited By ~ 3

Author(s):

Shigeyoshi Harihara ◽

Takeyuki Monna ◽

Sukeo Yamamoto

Keyword(s):

Liver Cirrhosis ◽

Prognostic Value

Download Full-text

Diagnostic and prognostic value of psoas muscle thickness and area in patients with liver cirrhosis and sarcopenia

Reports of Vinnytsia National Medical University ◽

10.31393/reports-vnmedical-2021-25(4)-06 ◽

2021 ◽

Vol 25 (4) ◽

pp. 551-558

Author(s):

V. M. Motsiuk ◽

N. O. Pentiuk

Keyword(s):

Skeletal Muscle ◽

Liver Cirrhosis ◽

Prognostic Value ◽

Psoas Muscle ◽

Muscle Thickness ◽

Diagnostic Value ◽

Reference Ranges ◽

Skeletal Muscle Index ◽

Male And Female ◽

Diagnostic And Prognostic Value

Annotation. Sarcopenia is a typical complication of liver cirrhosis (LC) and is associated with a poor prognosis. The skeletal muscle index is the most studied radiological marker of sarcopenia, but it’s using requires the qualification of a radiologist, specialized software, time reserve. The aim of the study: to investigate the relationship between different radiological markers of skeletal muscle mass, to determine their reference ranges for Ukrainian population and to assess their diagnostic and prognostic value in patients with LC. The study involved 216 healthy people and 147 patients with LC. During 18 months of follow-up 45 patients died from LC complications. Skeletal muscles were assessed by computed tomography. Skeletal muscle index (SMI), psoas muscle index (PMI), and transverse psoas muscle thickness (TPMT) at L3 were determined. Statistical data processing was performed in SPSS22. Diagnostic and prognostic value of SMI, PMI, TPMT were studied in ROC analysis. It was found that in Ukrainian population the reference ranges of SMI are >52.2 / 39.3 cm2/m2, PMI>6. 44 / 3.49 cm2/m2, TPMT>11.1 / 7.42 mm/m, in men / women, respectively. Sarcopenia was diagnosed in 54.9% and 86.3% of LC class B and C patients. PMI and TPMT had a high diagnostic value in sarcopenia detection (SMI≤52.2 and ≤39.3 cm2/m2) in male and female LC patients (AUC PMI 0.899 and 0.955, p˂0.001, AUC TPMT 0.884 and 0.942, p˂0.001). SMI, PMI and TPMT predicted one-and-a-half-year mortality in male and female LC patients (AUC SMI 0.815 and 0.786, p<0.001; AUC PMI 0.745 and 0.804, p<0.001; AUC TPMT 0.752 and 0.871, p<0.001). The optimal cut-off values for predicting death in male and female are: SMI≤49.1 and ≤38.4 cm2/m2; PMI≤5.99 and ≤3.30 cm2/m2; TPMT≤11.0 and ≤6.70 mm/m. Thus, routine assessment of PMI and TPMT in LC can identify patients with sarcopenia and high risk of complications.

Download Full-text

Prognostic Value of Serum Exosomal AHCY Expression in Hepatitis B-Induced Liver Cirrhosis

Frontiers in Medicine ◽

10.3389/fmed.2021.777452 ◽

2021 ◽

Vol 8 ◽

Author(s):

Ling Tong ◽

Cuilin Yan ◽

Minjie Wang ◽

Jiajia Yang ◽

Hongmei Wang ◽

...

Keyword(s):

Liver Cirrhosis ◽

Hepatitis B ◽

Prognostic Value ◽

Survival Curve ◽

Area Under The Curve ◽

Meld Score ◽

Mortality Prediction ◽

Operating Characteristics ◽

Serum Samples ◽

Prediction Ability

Objective: We aimed to investigate serum exosomal adenosylhomocysteinase (AHCY) expression in hepatitis B-induced liver cirrhosis (HBV-LC) patients and to determine the prognostic value of serum exosomal AHCY.Methods: We collected serum samples from 100 patients with chronic hepatitis B (CHB) and from 114 HBV-LC patients to test serum exosomal AHCY expression using ELISA.Results: Compared with the CHB and Grade A and B HBV-LC groups, the level of exosomal AHCY expression was significantly higher in the HBV-LC group [376.62 (291.50–448.02) vs. 248.12 (189.28–324.63), P > 0.001] and the Grade C HBV-LC group [408.70 (365.63–465.76) vs. 279.76 (215.16–336.07), P > 0.001], respectively. Serum exosomal AHCY expression and MELD score had a significant positive correlation (r = 0.844, P < 0.001). Survival curve analysis showed that patients with low exosomal AHCY expression had significantly longer survival than patients with high exosomal AHCY expression (P = 0.0038). The receiver operating characteristics (ROC) curve showed that the area under the curve (AUC) value for the mortality prediction ability of serum exosomal AHCY in HBV-LC patients was 0.921, which was higher than the values for the MELD score (AUC 0.815) and Child-Pugh classification (AUC 0.832), with a sensitivity and specificity of 93.41 and 76.00%, respectively.Conclusions: The serum exosomal AHCY level is a novel potential prognostic biomarker in HBV-LC patients, which may be great significance for the prognosis of HBV-LC patients.

Download Full-text

A Comparative Study of the Diagnostic and Prognostic Value of Squamous Cell Carcinoma Antigen and Alfa-foeto Protien in Hepatocellular Carcinoma Before and After Therapeutic Intervention

QJM ◽

10.1093/qjmed/hcaa052.028 ◽

2020 ◽

Vol 113 (Supplement_1) ◽

Author(s):

S Abdelhamid ◽

T M Alsakty ◽

H H Radwan ◽

M E Abouelmaaty ◽

A S Allam ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Squamous Cell Carcinoma ◽

Liver Cirrhosis ◽

Cell Carcinoma ◽

Squamous Cell ◽

Prognostic Value ◽

Control Group ◽

Squamous Cell Carcinoma Antigen ◽

Group I ◽

Group Ii

Abstract Background hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and it is one of the major causes of death, because of its high frequency and poor prognosis. Hepatocellular carcinoma is now a common malignancy in Egypt which usually develops on top of liver cirrhosis secondary to viral infection, as hepatitis C viruses increased the risk of HCC in the Egyptian patients. Aim of the Work was to verify the possibility of using the plasma squamous cell carcinoma antigen level as a tumor marker for hepatocellular carcinoma and to evaluate its prognostic value in management of HCC. Patients and Methods the study included 60 subjects divided into three groups: group I was 30 patients with hepatocellular carcinomas, group II was 15 patients with liver cirrhosis and group III was 15 normal subjects serving as a control group. Follow up of the patients who had HCC and undergone either RFA or TACE will be done after 1 month by measuring serum level of alfa feto protein & SCCA. Results the plasma SCCA level was significantly higher in group I patients (with HCC), than in the group II patients (cirrhosis) and control group. SCCA showed direct significant correlation with the most of laboratory data specially AST, INR, number and size of lesion and its values were decreased after intervention. Conclusion plasma SCCA is a sensitive and specific serum marker for the diagnosis and prognosis of HCC and combination of AFP and SCCA in screening and diagnosis of HCC yielded a better sensitivity in diagnosis of HCC.

Download Full-text

Prognostic value of lectin pathway molecules and complement proteins in ascitic fluid and blood in patients with liver cirrhosis

Scandinavian Journal of Gastroenterology ◽

10.1080/00365521.2017.1386710 ◽

2017 ◽

Vol 53 (1) ◽

pp. 64-69 ◽

Cited By ~ 2

Author(s):

Signe Glargaard ◽

Trine Boysen ◽

Katrine Pilely ◽

Peter Garred ◽

Henriette Ytting

Keyword(s):

Liver Cirrhosis ◽

Ascitic Fluid ◽

Prognostic Value ◽

Lectin Pathway ◽

Complement Proteins

Download Full-text

The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

Romanian Journal of Internal Medicine ◽

10.2478/rjim-2018-0007 ◽

2018 ◽

Vol 56 (3) ◽

pp. 182-192

Author(s):

Andrei Mihai Voiosu ◽

Paul Bălănescu ◽

Ioana Daha ◽

Bianca Smarandache ◽

Aurelia Rădoi ◽

...

Keyword(s):

Liver Cirrhosis ◽

Heart Disease ◽

Liver Disease ◽

Cardiac Dysfunction ◽

Prognostic Value ◽

Prospective Observational Study ◽

Cirrhotic Cardiomyopathy ◽

Cirrhotic Patients ◽

The Relationship ◽

Diagnostic And Prognostic Value

Abstract Background. We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy. Materials and methods. Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes. Results. 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 vs. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1). Conclusion. Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population.

Download Full-text